Plus Therapeutics, Inc. (PSTV) Bundle
Ever wondered how a small pharmaceutical company is tackling some of the toughest cancers? Plus Therapeutics, Inc. (PSTV), a clinical-stage company, is focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers. But with a market capitalization of just $12.75 million as of April 14, 2025, how does this company operate and what makes it tick? Keep reading to discover Plus Therapeutics' history, ownership structure, mission, operational mechanisms, and revenue generation strategies, and understand how it's making strides in the fight against cancer.
Plus Therapeutics, Inc. (PSTV) History
Plus Therapeutics, Inc. Founding Timeline
Year established
Plus Therapeutics, Inc. was founded in 2014.
Original location
The company is headquartered in Austin, Texas.
Founding team members
While specific details about all founding team members are not readily available in the provided search results, Marc Hedrick M.D. is a key figure associated with the establishment and leadership of the company. He served as President and CEO.
Initial capital/funding
Information regarding the precise initial capital or funding at the company's founding in 2014 is not available in the provided search results.
Plus Therapeutics, Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2014 | Company Founded | Established as a pharmaceutical company focused on developing innovative therapies for cancer. |
| 2018 | Acquisition of Rhenium-186 Nanoliposome Technology | Expanded the company's therapeutic pipeline with a promising new treatment modality. |
| 2020 | Initiation of ReSPECT-GBM Phase 1 Clinical Trial | Marked a critical step in evaluating the safety and efficacy of Rhenium-186 nanoliposome in patients with recurrent glioblastoma. |
| 2021 | FDA Orphan Drug Designation | The FDA granted Orphan Drug Designation to Rhenium-186 Nanoliposome for the treatment of glioblastoma. |
| 2023 | Completed Enrollment in ReSPECT-GBM Phase 1 Clinical Trial | Completed enrollment of adult recurrent glioblastoma patients in its ReSPECT-GBM phase 1 clinical trial. |
| 2024 | New Patent for Rhenium-186 Nanoliposome | The United States Patent and Trademark Office issued U.S. Patent No. 11,944,745, covering methods of using Rhenium-186 Nanoliposome for treating cancer. |
Plus Therapeutics, Inc. Transformative Moments
- Acquisition of Rhenium-186 Nanoliposome Technology: This acquisition significantly shaped the company's focus, providing a novel platform for targeted cancer therapy using radiotherapeutics.
- Advancement of ReSPECT-GBM Clinical Trial: Progressing to Phase 1 clinical trials for Rhenium-186 nanoliposome in recurrent glioblastoma was a pivotal step, demonstrating the company's commitment to clinical development and addressing unmet needs in cancer treatment.
- FDA Orphan Drug Designation: Receiving Orphan Drug Designation from the FDA for Rhenium-186 Nanoliposome underscored the potential of this therapy for a rare disease and provided incentives for further development.
To gain further insights into the company's goals, check out: Mission Statement, Vision, & Core Values of Plus Therapeutics, Inc. (PSTV).
Plus Therapeutics, Inc. (PSTV) Ownership Structure
Understanding the ownership structure of Plus Therapeutics, Inc. (PSTV) provides valuable insights into who controls the company and whose interests might be driving its strategic decisions. The company has a mix of institutional, retail, and insider ownership.
Plus Therapeutics, Inc.'s Current Status
Plus Therapeutics, Inc. is a public company, trading on the NASDAQ under the ticker symbol PSTV. This means that its shares are available for purchase by the general public.
Plus Therapeutics, Inc.'s Ownership Breakdown
The ownership of Plus Therapeutics, Inc. is distributed among various types of shareholders. Here's a breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Owners | 23.48% | Includes investment firms, hedge funds, and other institutions. |
| Retail Investors | 69.78% | Individual investors who hold shares of the company. |
| Insiders | 6.74% | Company officers and directors who own shares. |
Plus Therapeutics, Inc.'s Leadership
The leadership team is crucial for the direction and management of Plus Therapeutics, Inc. Key members include:
- Marc Hedrick, M.D. serves as the President and Chief Executive Officer.
- Andrew Sims is the Chief Financial Officer.
- Dr. Frank Lieberman is the Chief Medical Officer of the company.
To gain a deeper understanding of the values and goals that guide Plus Therapeutics, Inc., explore the Mission Statement, Vision, & Core Values of Plus Therapeutics, Inc. (PSTV).
Plus Therapeutics, Inc. (PSTV) Mission and Values
Plus Therapeutics aims to improve the lives of cancer patients through innovative therapies. The company is dedicated to developing targeted treatments with the potential to enhance efficacy and reduce side effects.
Plus Therapeutics' Core Purpose
Official mission statement
Plus Therapeutics' mission, as detailed in their 2024 proxy statement, is centered on:
- Developing and commercializing innovative, targeted radiotherapeutics for difficult-to-treat cancers.
- Focusing on therapies with the potential to improve patient outcomes and quality of life.
Vision statement
While a specific, formally declared vision statement is not explicitly provided in the company's latest filings, insights into Plus Therapeutics' long-term aspirations can be gleaned from their strategic objectives and corporate presentations. The vision can be inferred as:
- Becoming a leader in targeted radiotherapeutics for cancer.
- Establishing a pipeline of innovative therapies addressing unmet needs in oncology.
- Delivering significant value to patients, healthcare providers, and shareholders through groundbreaking treatments.
Company slogan/tagline
As of the latest information available, Plus Therapeutics does not have a prominently displayed or widely publicized official slogan or tagline. However, their core focus and activities suggest an implicit tagline centered around:
- Targeting Cancer, Improving Lives.
- Precision Radiotherapeutics for a Better Tomorrow.
To gain more insights into Plus Therapeutics' financial standing, see Breaking Down Plus Therapeutics, Inc. (PSTV) Financial Health: Key Insights for Investors.
Plus Therapeutics, Inc. (PSTV) How It Works
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focusing on the development of targeted radiotherapeutics for difficult-to-treat cancers.
Plus Therapeutics' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Rhenium-186 Nanoliposome (186RNL) | Recurrent Glioblastoma (GBM) and Leptomeningeal Metastases (LM) | Radioactive drug delivered directly into the tumor using convection-enhanced delivery (CED); designed to target and destroy cancer cells while sparing healthy tissue. |
Plus Therapeutics' Operational Framework
Plus Therapeutics operates through a focused clinical development pathway, concentrating on its lead drug candidate, Rhenium-186 Nanoliposome (186RNL). Key aspects of their operational framework include:
- Clinical Trials: Conducting Phase 1 and Phase 2 clinical trials to evaluate the safety and efficacy of 186RNL in treating recurrent Glioblastoma and Leptomeningeal Metastases.
- Convection-Enhanced Delivery (CED): Utilizing CED to administer the drug directly into the tumor, ensuring targeted delivery and minimizing systemic exposure.
- Manufacturing: Focusing on the manufacturing and quality control of 186RNL to meet regulatory standards for clinical use.
- Regulatory Strategy: Working closely with regulatory agencies like the FDA to secure approvals and advance the drug through the development pipeline.
- Collaboration: Partnering with leading cancer centers and research institutions to conduct clinical trials and expand the understanding of 186RNL's potential.
More insights about company's mission, vision, and core values can be found here: Mission Statement, Vision, & Core Values of Plus Therapeutics, Inc. (PSTV).
Plus Therapeutics' Strategic Advantages
Plus Therapeutics' strategic advantages stem from its innovative approach to cancer treatment and its focus on difficult-to-treat tumors:
- Targeted Radiotherapy: The use of targeted radiotherapy allows for precise treatment, potentially reducing side effects compared to traditional radiation therapy.
- Nanoliposome Technology: The nanoliposome delivery system enhances drug penetration and retention within the tumor.
- Orphan Drug Designation: 186RNL has received orphan drug designation for certain indications, which can provide regulatory and financial benefits.
- Experienced Team: A team with expertise in radiopharmaceuticals, oncology, and drug development guides the company's strategy and operations.
Plus Therapeutics, Inc. (PSTV) How It Makes Money
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company primarily generates revenue through strategic collaborations and licensing agreements related to its drug development programs.
Plus Therapeutics, Inc.'s Revenue Breakdown
As a clinical-stage company, revenue streams are subject to variability based on the progress of clinical trials, partnerships, and licensing deals. The following is a hypothetical revenue breakdown based on typical activities of a company in this sector. It's important to note that without specific 2024 fiscal year data, this is an illustrative example.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Licensing Agreements | 60% | Increasing |
| Research and Development Collaborations | 40% | Stable |
Plus Therapeutics, Inc.'s Business Economics
Plus Therapeutics, Inc.'s business economics are characterized by high upfront research and development costs, long development timelines, and significant regulatory hurdles. Key aspects include:
- Drug Development Costs: Significant investment in preclinical and clinical trials to prove safety and efficacy.
- Regulatory Approval: Navigating the FDA approval process, which can be lengthy and expensive.
- Intellectual Property: Protecting drug candidates with patents to maintain market exclusivity.
- Partnerships: Collaborating with other pharmaceutical companies or research institutions to share costs and expertise.
- Market Opportunity: Targeting niche cancer markets with unmet needs to achieve premium pricing.
Plus Therapeutics, Inc.'s Financial Performance
As a clinical-stage company, financial performance is heavily influenced by research and development expenses and the ability to secure funding. Key financial aspects include:
- Cash Runway: Monitoring cash reserves to fund ongoing clinical trials and operations.
- R&D Expenses: A significant portion of operating expenses is dedicated to advancing drug candidates through clinical development.
- Funding: Raising capital through equity offerings, debt financing, or strategic partnerships.
- Net Loss: Typically, the company will report a net loss due to high R&D spending until a product is commercialized.
- Strategic Focus: For more information about the company's goals, check out: Mission Statement, Vision, & Core Values of Plus Therapeutics, Inc. (PSTV).
Plus Therapeutics, Inc. (PSTV) Market Position & Future Outlook
Plus Therapeutics is strategically positioned to advance its radiotherapeutic technologies, particularly focusing on its lead drug candidate, Rhenium-186 Nanoliposome (186RNL), for recurrent glioblastoma (rGBM) and other cancers. The company's future hinges on successful clinical trial outcomes, regulatory approvals, and effective commercialization strategies in a competitive oncology market.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Plus Therapeutics, Inc. | Relatively Small, but growing | Proprietary 186RNL technology for targeted radiotherapy |
| Novocure | ~30% (in GBM treatment) | Optune device providing Tumor Treating Fields (TTFields) therapy |
| Bristol Myers Squibb | Significant, but varies by cancer type | Broad portfolio of immuno-oncology drugs like Opdivo |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential FDA approval and commercialization of 186RNL for rGBM, addressing a significant unmet medical need. | Clinical trial failures or delays in regulatory approvals for 186RNL. |
| Expansion of 186RNL therapy to other cancers beyond rGBM, broadening the market reach. | Competition from established pharmaceutical companies with greater resources and broader product portfolios. |
| Strategic partnerships or collaborations to enhance research, development, and commercialization efforts. | Reliance on successful fundraising and capital management to sustain operations and clinical development. As of the fiscal year 2024, Plus Therapeutics reported a net loss of $23.7 million, underscoring the critical need for effective financial strategies. |
Industry Position
Plus Therapeutics occupies a niche position within the oncology therapeutics market, focusing on targeted radiotherapeutics. Key aspects of their industry standing include:
- Innovative Technology: The company's 186RNL platform represents a novel approach to cancer treatment by delivering radiation directly to tumor cells.
- Focus on Unmet Needs: Plus Therapeutics is addressing difficult-to-treat cancers like recurrent glioblastoma, where current treatment options are limited.
- Clinical Development Stage: As a clinical-stage company, Plus Therapeutics' value is heavily dependent on the success of its ongoing and future clinical trials.
- As of the fiscal year 2024, Plus Therapeutics reported cash and cash equivalents totaling $13.8 million, highlighting the importance of strategic financial management to support ongoing research and development initiatives.
For more insights into Plus Therapeutics, Inc., consider reading: Exploring Plus Therapeutics, Inc. (PSTV) Investor Profile: Who’s Buying and Why?
Plus Therapeutics, Inc. (PSTV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.